Novel stem cell protein discovered may play an essential role in finding a cure for blood cancer. The findings of the study are published in the journal Blood.
The study, done on mice, suggests a stem cell protein called Asrij is a novel regulator of wild type tumor suppressor p53 stability in hematopoietic stem cells (HSCs).
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
Advertisement
‘Inactivation of the tumor suppressor p53 is necessary for unrestrained growth of cancers.
’
Read More..
Tweet it Now
Read More..
It could help design targeted therapies for myeloproliferative disease, a group of slow-growing blood cancers, according to researchers, including Maneesha S. Inamdar from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru.
"We provide a new mouse model resembling myeloproliferative disease and identify a post-translational regulator of wild type p53 essential for maintaining HSC quiescence that could be a potential target for pharmacological intervention," the team said.
![Arthritis and Psoriasis Medication can Increase Survival of Patients With Blood Cancers]( "Arthritis and Psoriasis Medication can Increase Survival of Patients With Blood Cancers")
Etanercept, an existing tumor necrosis factor-alpha blocker allows transplanted stem cells to thrive in new host.
According to the study, inactivation of the tumor suppressor p53 is essential for unrestrained growth of cancers. But only 11 percent of hematological malignancies has mutant p53.
Mechanisms that cause wild type p53 dysfunction and promote leukemia are inadequately deciphered, suggests the study.
The stem cell protein Asrij is misexpressed in several human hematological malignancies and implicated in the p53 pathway and DNA damage response, the team said.
For the study, the team generated the first Asrij null (knockout, KO) in mice and showed they are viable and fertile with no gross abnormalities. However, by six months, they exhibited increased peripheral blood cell counts, splenomegaly and expansion of bone marrow HSCs with a higher myeloid output.
Source: IANS
Arthritis and Psoriasis Medication can Increase Survival of Patients With Blood Cancers
Etanercept, an existing tumor necrosis factor-alpha blocker allows transplanted stem cells to thrive in new host.
Advertisement
According to the study, inactivation of the tumor suppressor p53 is essential for unrestrained growth of cancers. But only 11 percent of hematological malignancies has mutant p53.
Mechanisms that cause wild type p53 dysfunction and promote leukemia are inadequately deciphered, suggests the study.
The stem cell protein Asrij is misexpressed in several human hematological malignancies and implicated in the p53 pathway and DNA damage response, the team said.
For the study, the team generated the first Asrij null (knockout, KO) in mice and showed they are viable and fertile with no gross abnormalities. However, by six months, they exhibited increased peripheral blood cell counts, splenomegaly and expansion of bone marrow HSCs with a higher myeloid output.
Source: IANS
Vitamin C May Encourage Blood Cancer Stem Cells To Die
Vitamin C activates demethylation of TET2 enzyme, which signals stem cells to mature and die.
Advertisement
Arthritis Drug can Treat Rare Type of Blood CancerPolycythemia Vera is a rare type of blood disorder which has high blood cell count. Arthritis drug, methotrexate can effectively treat this disorder. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Shorter radiation course is just as good as the regular one for women choosing breast reconstruction after mastectomy, saving time and money.
HAMMR's small size permits minimally invasive implantation, monitoring cancer status, and dynamically adjusting immunotherapy, akin to a glucose monitor.
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
